Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

REGN Quantitative Stock Analysis - Benjamin Graham May 03, 2025 — 09:15 am EDT Written by John Reese for Validea -> ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.35% to $564.64 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to ...

Regeneron is down 20.5% since the beginning of the year, and at $568.91 per share, it is trading 52.7% below its 52-week high of $1,202 from August 2024.

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $57,109.53 today based on a price of $563.10 for REGN at the time of writing.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials of itepekimab in chronic obstructive pulmonary disease (COPD) patients ...

Regeneron (REGN) stock drops 18% as trial data for COPD therapy developed with Sanofi (SNY) leads to a downgrade at Wells Fargo. Read more here.

REGN Factor-Based Stock Analysis - Benjamin Graham March 12, 2025 — 12:06 pm EDT Written by John Reese for Validea -> ...

Shares of Regeneron Pharmaceuticals Inc. REGN shed 1.24% to $522.68 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.94 ...